AstraZeneca plc (LON:AZN)‘s stock had its “overweight” rating reaffirmed by analysts at Barclays PLC in a research note issued on Monday. They presently have a GBX 5,500 ($71.62) price target on the biopharmaceutical company’s stock. Barclays PLC’s target price points to a potential upside of 20.51% from the stock’s previous close.

Several other equities analysts have also recently issued reports on the stock. Deutsche Bank AG reduced their price target on shares of AstraZeneca plc from GBX 5,700 ($74.23) to GBX 5,300 ($69.02) and set a “buy” rating on the stock in a research report on Thursday, August 3rd. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($50.79) price target on shares of AstraZeneca plc and gave the company a “sell” rating in a research report on Wednesday, August 2nd. Shore Capital reiterated a “hold” rating on shares of AstraZeneca plc in a research report on Wednesday, August 2nd. UBS AG set a GBX 4,550 ($59.25) price target on shares of AstraZeneca plc and gave the company a “neutral” rating in a research report on Wednesday, August 2nd. Finally, Jefferies Group LLC reduced their price target on shares of AstraZeneca plc from GBX 4,900 ($63.81) to GBX 4,400 ($57.30) and set a “hold” rating on the stock in a research report on Tuesday, August 1st. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of GBX 4,937.43 ($64.30).

AstraZeneca plc (LON:AZN) opened at 4538.50 on Monday. The company’s market cap is GBX 57.46 billion. The stock’s 50 day moving average is GBX 5,022.16 and its 200-day moving average is GBX 4,861.45. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00.

TRADEMARK VIOLATION NOTICE: “AstraZeneca plc (AZN) Rating Reiterated by Barclays PLC” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/09/astrazeneca-plc-azn-rating-reiterated-by-barclays-plc.html.

In related news, insider Nazneen Rahman acquired 39 shares of the stock in a transaction that occurred on Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($56.91) per share, for a total transaction of £1,704.30 ($2,219.43).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.